Kappos, Ludwig and Li, David and Calabresi, Peter A. and O'Connor, Paul and Bar-Or, Amit and Barkhof, Frederik and Yin, Ming and Leppert, David and Glanzman, Robert and Tinbergen, Jeroen and Hauser, Stephen L.. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, Vol. 378, no. 9805. pp. 1779-1787.
Full text not available from this repository.
Official URL: http://edoc.unibas.ch/dok/A6004708
Downloads: Statistics Overview
Abstract
B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.
| Faculties and Departments: | 03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos) 03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos) |
|---|---|
| UniBasel Contributors: | Kappos, Ludwig |
| Item Type: | Article, refereed |
| Article Subtype: | Research Article |
| Publisher: | The Lancet |
| ISSN: | 0140-6736 |
| Note: | Publication type according to Uni Basel Research Database: Journal article |
| Identification Number: | |
| Last Modified: | 06 Dec 2013 09:35 |
| Deposited On: | 06 Dec 2013 09:35 |
Repository Staff Only: item control page